Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals Trading Up 0.5 %
NASDAQ:MACK traded up $0.02 on Friday, reaching $4.22. The company had a trading volume of 12,951 shares, compared to its average volume of 59,058. The company's fifty day moving average is $5.39 and its 200 day moving average is $5.72. Merrimack Pharmaceuticals has a 52-week low of $3.66 and a 52-week high of $7.41.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Merrimack Pharmaceuticals in a research report on Tuesday, August 9th. They set a "sell" rating on the stock.
Insider Activity at Merrimack Pharmaceuticals
In related news, Director Noah G. Levy purchased 20,938 shares of the stock in a transaction that occurred on Tuesday, June 14th. The stock was acquired at an average cost of $5.17 per share, with a total value of $108,249.46. Following the transaction, the director now owns 1,010,515 shares of the company's stock, valued at approximately $5,224,362.55. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders purchased 35,478 shares of company stock valued at $188,276. 25.80% of the stock is owned by insiders.